Table 2.
RA | RA‐HTN | ||
---|---|---|---|
(n = 13) | (n = 17) | P | |
RA duration (years) | 7.6 (4.6–12.4) | 5.5 (2.9–10.5) | 0.443 |
RF positive, n (%) | 9 (69) | 10 (59) | 0.768 |
Swollen joints, n (%) | 5.2 (2.9–9.0) | 2.6 (1.6–4.0) | 0.045 |
Tender joints, n (%) | 6.7 (2.8–14.7) | 3.5 (1.7–6.7) | 0.194 |
DAS28‐CRP | 4.8 ± 1.9 | 3.7 ± 1.2 | 0.063 |
Disease activity, n (%) | |||
Remission | 4 (31) | 5 (31) | 0.088 |
Low disease activity | 3 (23) | 9 (56) | |
High disease activity | 6 (46) | 2 (13) | |
VAS, % | 36.8 (21.7–62.0) | 12.9 (5.3–30.1) | 0.047 |
DMARD, n (%) | 11 (85) | 15 (88) | 0.773 |
Number of DMARDs | 1.8 (1.2–2.4) | 1.8 (1.3–2.2) | 0.850 |
Methotrexate, n (%) | 8 (62) | 12 (71) | 0.602 |
Hydroxychloroquine, n (%) | 5 (38) | 10 (59) | 0.269 |
Sulfasalazine, n (%) | 4 (31) | 3 (18) | 0.400 |
Leflunomide, n (%) | 2 (15) | 1 (6) | 0.390 |
Glucocorticoid, n (%) | 1 (8) | 6 (35) | 0.077 |
Prednisolone, n (%) | 1 (8) | 4 (24) | 0.249 |
Prednisolone dose (mg) | 3 | 5.3 ± 3 | 0.534 |
Intramuscular, n (%) | 0 | 1 (6) | 0.374 |
Intra‐articular, n (%) | 0 | 1 (6) | 0.374 |
NSAID, n (%) | 5 (38) | 6 (35) | 0.858 |
Opioid, n (%) | 6 (46) | 7 (41) | 0.785 |
Weak, n (%) | 5 (38) | 7 (41) | 0.880 |
Strong, n (%) | 1 (8) | 0 | 0.245 |
Biological agent, n (%) | 4 (31) | 3 (18) | 0.400 |
TNF‐α inhibitor, n (%) | 4 (31) | 1 (6) | 0.070 |
Certolizumab, n (%) | 2 (15) | 0 | 0.094 |
Etanercept, n (%) | 2 (15) | 0 | 0.094 |
Golilumab, n (%) | 0 | 1 (6) | 0.374 |
Rituximab, n (%) | 0 | 2 (12) | 0.201 |
Values expressed as the mean ± SD for continuous variables (parametric) and frequency (percentage) for discrete variables. Non‐parametric data were (natural) log transformed and are displayed as the geometric mean (95% confidence intervals). Statistical differences were tested using an independent t test for continuous variables and Pearson's chi‐square test for categorical data. Significance: P ≤ 0.05.
DAS, disease activity score; DMARD, disease modifying anti‐rheumatic drug; NSAID, non‐steroidal anti‐inflammatory drug; RF, rheumatoid factor.